A commercial-stage psychedelic drug manufacturer.
Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF) produces finished-dose psilocybin and MDMA capsules for regulated therapeutic use. The Company operates a Health Canada GMP-compliant facility in Princeton, British Columbia, and holds a Drug Establishment Licence authorizing commercial manufacture, packaging, testing, and international export of controlled drug products.
Active supply operations began under the Australian Authorized Prescriber Scheme in 2024. Product is dispensed to patients through authorized clinics for post-traumatic stress disorder and treatment-resistant depression.
The Company is structured to scale into additional jurisdictions as regulatory access develops, including the United States upon federal rescheduling.
Commercial today
MDMA and psilocybin capsules in the hands of authorized prescribers in Australia. Revenue recognized since Q2 2024.
GMP at the core
Health Canada Drug Establishment Licence. International export authorization. Built to pharmaceutical standards.
Direct to clinic
No middlemen. We supply authorized clinics, pharmacies, and clinical trial sponsors directly.
Rescheduling-ready
Infrastructure, quality systems, and regulatory posture in place to scale into U.S. therapeutic access as it opens.